
Dexamethasone Intracameral Drug-Delivery Suspension for Post-Op Inflammation
Daniel Kiernan, MD, discusses the results of a study examining dexamethasone intracameral drug-delivery suspension compared with topical corticosteroids for inflammation following vitreoretinal surgery.
New research due to be presented at the
Carried out by Daniel Kiernan, MD, a vitreoretinal surgeon with the Ophthalmic Consultants of Long Island, results of the retrospective comparison indicate the approach could allow for greater anterior chamber cell clearing at 7 days post-surgery than topical corticosteroids.
In an effort to further evaluate whether the sustained release of medication through dexamethasone intracameral drug-delivery suspension could sufficiently treat postoperative inflammation compared with daily topical corticosteroids, Kiernan conducted the analysis using a case-matched cohort of 54 patients. Of the 54, 27 eyes of 27 patients received dexamethasone intracameral drug-delivery suspension and 27 eyes of 27 patients received corticosteroid drops for 4 weeks.
Of note, all 54 patients included in the study had a preoperative BCVA of 20/20 to light perception.
The primary efficacy outcome of the study was anterior chamber cell clearing—defined as 0 cells—in the study eye at postoperative day 7. Kiernan also assessed for serious ocular events through day 90.
Upon analysis, anterior chamber cell clearing occurred in 67% of the intracameral dexamethasone group compared to 37% of patients treated with topical corticosteroids (P=.029). Additionally, no serious ocular adverse events were noted up to postoperative day 90.
To learn more about dexamethasone intracameral drug-delivery suspension and its use in a clinical setting, HCPLive® reached out to Kiernan to take part in a special ARVO 2020 edition of the DocTalk Podcast.
This study, "


























































